Clinical Trials Browser

Phase 2 × Withdrawn × INDUSTRY × Clear all

NCT07511972 2026-04-06

Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Phase 2 Withdrawn

CRC

NCT02143804 2026-04-02

exBOND

Phase 2 Withdrawn

Adenoviridae Infections, Urinary Bladder Neoplasms

NCT06829199 2026-02-19

MK-5890-003

Phase 2 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07323576 2026-02-09

INAVO-CRC

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT06068881 2026-01-30

Mandolin

Phase 2 Withdrawn

Lymphoma, Follicular

NCT06646016 2025-12-26

EPIC

Phase 2 Withdrawn

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT07026916 2025-11-17

A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT06557278 2025-10-21

COMUNITY

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT06555263 2025-08-22

Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04571710 2025-07-24

A Trial of SHR1258 in Patients With Biliary Tract Cancer

Phase 2 Withdrawn

Gastrointestinal

Biliary Tract Neoplasms

NCT06940804 2025-07-02

AVENTURINE

Phase 2 Withdrawn

Testicular Germ Cell Tumor, Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms

NCT06839872 2025-06-05

BOSS

Phase 2 Withdrawn

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02077621 2025-06-04

Study of PG2 Injection for Improving Fatigue in Patients After Palliative Abdominal Surgery for Cancer

Phase 2 Withdrawn

Fatigue, Neoplasms

NCT00535314 2025-05-31

Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma

Phase 2 Withdrawn

Melanoma

NCT04655807 2025-04-27

DUET

Phase 2 Withdrawn

Crohn Disease

NCT05126342 2025-04-06

Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi

Phase 2 Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05743270 2025-03-11

Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

Phase 2 Withdrawn

Squamous Cell Carcinoma of Head and Neck

NCT03554109 2025-02-21

TNBC

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT03563144 2025-02-21

QUILT-3.088: NANT Pancreatic Cancer Vaccine

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT03574649 2025-02-21

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT06233903 2025-01-21

18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System

Phase 2 Withdrawn

Neuroblastoma, Paraganglioma, Pheochromocytoma

NCT05456165 2024-12-31

Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT06331598 2024-12-24

IMperator

Phase 2 Withdrawn

Other solid neoplasm

Solid Tumors

NCT06219733 2024-12-09

MP-VAC-206

Phase 2 Withdrawn

Dermoid Cyst

NCT06424717 2024-09-27

Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)

Phase 2 Withdrawn

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06099418 2024-09-20

Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.

Phase 2 Withdrawn

Uterine Cervical Neoplasms, Neoplasm Metastasis, Recurrence

NCT00756782 2024-09-04

A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma

Phase 2 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular

NCT06105008 2024-08-23

Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT06518538 2024-08-15

Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT05212701 2024-04-30

To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms, Fatigue

NCT06046274 2024-04-30

GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer

Phase 2 Withdrawn

Advanced Endometrial Cancer

NCT05338580 2024-04-15

Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors

Phase 2 Withdrawn

DermatologicGenitourinaryThoracic

First-line Non-small-cell Lung Cancer

NCT05033132 2024-03-28

A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer

Phase 2 Withdrawn

Uterine Cervical Neoplasms

NCT05726682 2024-03-05

A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Phase 2 Withdrawn

Allogenic Stem Cell Transplantation

NCT06052423 2024-03-04

ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer

Phase 2 Withdrawn

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT02746328 2024-02-26

Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass

Phase 2 Withdrawn

ER+ and AR+ Breast Cancer

NCT05125562 2024-02-13

Extracellular Vesicles Infusion Treatment for Mild-to-Moderate COVID-19

Phase 2 Withdrawn

COVID-19, Lymphoma, Follicular

NCT02531854 2023-12-19

A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT05927012 2023-11-24

A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).

Phase 2 Withdrawn

Classical hematologyMyeloid

Myelodysplastic Syndromes, Anemia, Iron-Deficiency, Primary Myelofibrosis

NCT05998941 2023-11-22

A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer

Phase 2 Withdrawn

Uterine Cervical Neoplasms

NCT02232646 2023-11-14

A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies

Phase 2 Withdrawn

Carcinoma, Renal Cell, Carcinoma, Transitional Cell

NCT05321498 2023-09-28

Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation

Phase 2 Withdrawn

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Tauopathies, Cognitive Dysfunction

NCT05284214 2023-09-15

SALIENT

Phase 2 Withdrawn

Other solid neoplasm

Solid Tumor

NCT05359692 2023-09-15

INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2 Withdrawn

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Squamous Cell

NCT05825365 2023-08-14

PROTECT

Phase 2 Withdrawn

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT05809895 2023-07-24

AdvanTIG-211

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT05561491 2023-06-22

A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients

Phase 2 Withdrawn

Melanoma, Neoplasm Metastasis

NCT05411679 2023-06-12

EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer

Phase 2 Withdrawn

GastrointestinalThoracic

Stomach Neoplasms, Small Cell Lung Carcinoma

NCT04675450 2023-06-08

NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy

Phase 2 Withdrawn

Breast Neoplasms, Peripheral Nervous System Diseases

NCT04699968 2023-06-07

A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung